Immunoprecise Antibodies Ltd (IPA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Immunoprecise Antibodies Ltd (IPA) has a cash flow conversion efficiency ratio of -0.048x as of April 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.14 Million) by net assets ($23.63 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Immunoprecise Antibodies Ltd - Cash Flow Conversion Efficiency Trend (1997–2025)
This chart illustrates how Immunoprecise Antibodies Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Immunoprecise Antibodies Ltd total liabilities for a breakdown of total debt and financial obligations.
Immunoprecise Antibodies Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Immunoprecise Antibodies Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bokwang Industry Co Ltd
KQ:225530
|
0.069x |
|
Pelican Acquisition Corporation Ordinary Shares
NASDAQ:PELI
|
-0.001x |
|
Neuronetics Inc
NASDAQ:STIM
|
0.035x |
|
Rorze Systems Corporation
KQ:071280
|
-0.028x |
|
Chainqui Construction Development Co Ltd
TW:2509
|
-0.121x |
|
Sterling Tools Limited
NSE:STERTOOLS
|
0.055x |
|
SkyWorld Development Berhad
KLSE:5315
|
N/A |
|
Skardin Industrial
TWO:3466
|
0.001x |
Annual Cash Flow Conversion Efficiency for Immunoprecise Antibodies Ltd (1997–2025)
The table below shows the annual cash flow conversion efficiency of Immunoprecise Antibodies Ltd from 1997 to 2025. For the full company profile with market capitalisation and key ratios, see IPA market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-04-30 | $23.63 Million | $-6.41 Million | -0.271x | -116.75% |
| 2024-04-30 | $33.92 Million | $-4.25 Million | -0.125x | +63.52% |
| 2023-04-30 | $57.80 Million | $-19.83 Million | -0.343x | -160.37% |
| 2022-04-30 | $75.28 Million | $-9.92 Million | -0.132x | -1150.23% |
| 2021-04-30 | $56.92 Million | $-600.00K | -0.011x | +88.57% |
| 2020-04-30 | $15.09 Million | $-1.39 Million | -0.092x | +48.03% |
| 2019-04-30 | $18.07 Million | $-3.21 Million | -0.177x | +34.01% |
| 2018-04-30 | $12.70 Million | $-3.42 Million | -0.269x | -15.23% |
| 2017-04-30 | $3.09 Million | $-721.65K | -0.233x | -174.62% |
| 2016-04-30 | $908.26K | $284.09K | 0.313x | +80.64% |
| 2015-04-30 | $-208.52K | $-36.11K | 0.173x | -40.10% |
| 2014-04-30 | $-161.21K | $-46.60K | 0.289x | +1338.08% |
| 2013-04-30 | $-215.66K | $-4.33K | 0.020x | -98.18% |
| 2012-04-30 | $-119.89K | $-132.72K | 1.107x | +318.14% |
| 2011-04-30 | $158.40K | $-80.39K | -0.507x | -793.11% |
| 2010-04-30 | $5.43 Million | $-308.49K | -0.057x | -147.62% |
| 2009-04-30 | $6.78 Million | $-155.68K | -0.023x | +77.54% |
| 2008-04-30 | $5.12 Million | $-523.45K | -0.102x | -86.65% |
| 2007-04-30 | $5.43 Million | $-297.31K | -0.055x | -93.48% |
| 2006-04-30 | $3.91 Million | $-110.59K | -0.028x | -45.53% |
| 2005-04-30 | $4.23 Million | $-82.20K | -0.019x | +84.83% |
| 2004-04-30 | $1.39 Million | $-178.69K | -0.128x | +33.99% |
| 2003-04-30 | $867.54K | $-168.38K | -0.194x | +52.10% |
| 2002-04-30 | $691.56K | $-280.23K | -0.405x | -1206.41% |
| 2001-04-30 | $262.24K | $-8.13K | -0.031x | +94.10% |
| 2000-04-30 | $396.53K | $-208.54K | -0.526x | -319.83% |
| 1999-04-30 | $1.62 Million | $-202.94K | -0.125x | -58.13% |
| 1998-04-30 | $2.86 Million | $-226.81K | -0.079x | -165.55% |
| 1997-04-30 | $3.63 Million | $-108.20K | -0.030x | -- |
About Immunoprecise Antibodies Ltd
ImmunoPrecise Antibodies Ltd. operates as an AI-driven biotherapeutic research, technology, and scientifically robust life science company. It discovers and develops customized and novel antibodies by generating proprietary and patented processes, procedures, and innovative approaches to antibody discovery, development, and production. The company was incorporated in 1983 and is headquartered in … Read more